Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

March 23, 2021March 23, 2021

Veto T-cells Boost Success of Stem Cell Transplant for SCD

News

Adding Cell Source’s special class of immune cell, Veto T-cells, to blood stem cells from an unrelated donor led to a successful transplant and to the production of normal red blood ... Read more

February 2, 2021February 2, 2021

Lonza to Produce Aruvant’s ARU-1801 for Pivotal Trial

News

A recent manufacturing agreement between Aruvant Sciences and Lonza will advance the development of ARU-1801, an investigational gene therapy for the treatment of sickle cell disease (SCD). Under the agreement, Lonza will ... Read more

January 26, 2021January 26, 2021

Trial Will Test New Combination Regimen for Stem Cell Collection

News

A clinical trial will assess a combination of MGTA-145 plus plerixafor as a new regimen for aiding in the collection of blood stem cells from adults and adolescents with sickle ... Read more

December 10, 2020December 10, 2020

Oxbryta May Be SCD Blood Transfusions Option in Pandemic, Case Report Finds

News

Treatment with Oxbryta (voxelotor) may be a feasible alternative to blood transfusions for sickle cell disease (SCD) patients who are experiencing respiratory distress and pneumonia related to COVID-19, a case ... Read more

October 27, 2020October 27, 2020

Phase 1 Trial of Oral FTX-6058 to Promote Fetal Hemoglobin Set to Open

News

FTX-6058, an investigational oral treatment being developed by Fulcrum Therapeutics for sickle cell disease (SCD) and beta-thalassemia, is entering a Phase 1 clinical trial in healthy volunteers, the company announced. The trial (NCT04586985), not ... Read more

September 29, 2020September 29, 2020

Gene Therapy LentiGlobin Granted Priority Medicines Designation for SCD in EU

News

Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for diseases ... Read more

September 24, 2020September 24, 2020

Gene-editing Therapy CTX001 Granted Priority Medicines Designation for Severe SCD in EU

News

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made ... Read more

August 20, 2020August 20, 2020

Medical Marijuana Reduces Pain and Hospital Visits in SCD Patients, Study Indicates

News

Use of medical marijuana to ease pain is associated with fewer visits to the hospital in people with sickle cell disease (SCD), a study suggests. Patients given medical marijuana felt ... Read more

August 11, 2020August 11, 2020

Parallel, Pitt Team Up to Study Medical Marijuana for Treating SCD Symptoms

News

The cannabis company Parallel, which aims to improve quality of life with its products, has launched a 10-year collaboration with the University of Pittsburgh, known as Pitt, to investigate the potential ... Read more

August 6, 2020August 6, 2020

Nearly $1M Grant to Support Work Into Reactivating Fetal Hemoglobin

News

The National Heart, Lung, and Blood Institute (NHLBI) awarded nearly $1 million to Athena Starlard-Davenport, a professor at the University of Tennessee Health Science Center (UTHSC), to support work into ... Read more